Agios Pharmaceuticals, Inc.
AGIOHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Valued at $2.36B, AGIO is a mid-cap name in its sector. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Market Cap
$2.36B
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
-8.63
EPS (TTM)
$-7.42
EPS (Fwd)
$-4.59
ROE
-32.8%
ROA
-21.7%
Cash
$737.0M
Total Debt
$35.7M
Free CF
-$267.2M
52W Change
-1.0%
Annual Financials
Cash vs Debt
Agios Pharmaceuticals, Inc. holds $737.0M in cash against $35.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$267.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -32.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $14.2M (2022) to $54.0M (2025), reflecting a 279% increase over the period.
AGIO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, AGIO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Agios Pharmaceuticals, Inc.'s trajectory.